Accepted answer
8 weeks is 56 days, and the first question about any marker is whether 56 days is long enough for it to have finished moving. LDL-C is calculated rather than measured on most panels, and the calculation is sensitive to the triglyceride figure sitting next to it. Against 56 days that puts the marker well inside its own settling time, so the value is reporting a new steady state rather than a transient. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 56 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Headline results, principal programmes
| Trial | Agent | n | Duration | Primary result |
|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Decide the action for each result before you order the test.
2Thank you — this is the answer I was looking for. – tandem_gradient 6 months ago add a comment